资讯
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Th
Galderma, the pure-play dermatology category leader, is presenting new three-year data from the ARCADIA long-term extension study, demonstrating that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itc